UPDATE 1-Genzyme says combo approach aids leukemia patients

Mon Dec 7, 2009 4:40pm EST

* Campath-Fludara combo slows progression of leukemia

* Genzyme to seek expanded label indication based on data

CHICAGO, Dec 7 (Reuters) - Genzyme Corp (GENZ.O) on Monday said patients taking its leukemia drug Campath in combination with Fludara in a clinical trial saw less disease progression than patients taking Fludara alone.

Genzyme said it intends...

admin

Researchers from the UK have reported a 48% progression-free survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) following reduced-intensity allogeneic stem cell transplantation. The details of this Phase II study appeared in the January 20, 2009 issue of the Journal of Clinical Oncology.[1]

Reduced-intensity allogeneic stem cell transplants for patients with relapsed low- and high-grade lymphoma has been effective, potentially curative therapy. A previous study...

admin

Combination alemtuzumab and rituximab may be an effective early treatment for patients with high-risk chronic lymphocytic leukemia, according to data from a phase-2 trial.

Researchers examined the safety and efficacy of alemtuzumab (Campath, Ilex Pharmaceuticals) and rituximab (Rituxan, Genentech) for the early treatment of high-risk CLL in 30 patients who were previously untreated and had at least one marker for high-risk disease.

Patients were assigned to subcutaneous...

admin